

Contents

	Page
Summary	3
Introduction	3
The Benefit-and-Cost Model for Medical Interventions.	3
Peptic Ulcer Disease.	4
Cimetidine.	4
The Benefit-and-Cost Model Applied to Cimetidine.	5
Review of Benefit-and-Cost Analyses of Cimetidine.	6
Suggestions for Further Research	6
Introduction	6
The Benefit-and-Cost Model for Medical Interventions	7
Peptic Ulcer Disease	10
Definition and Etiology	10
Symptoms and Diagnosis	11
Treatment and Natural History	11
Epidemiologic Patterns	13
Cost of Illness	18
Summary	22
Cimetidine	23
Physiologic Rationale and Development	23
Diffusion	24
The Benefit-and-Cost Model Applied to Cimetidine	25
Elements in the Analysis	25
Clinical Effects	26
Health System Effects	39
Outcome	46
Summary	48
Review of Benefit-and-CostAnalyses of Cimetidine	49
Available Analyses	49
The Study by Robinson Associates, Inc.	49
Guidelines for Review of Health Care Cost Analyses	57
Suggestions for Further Research.	58
References	59

LIST OF TABLES

Table No.	Page
1. Selected Contemporary Interventions Used in Peptic Ulcer Disease	7
2. Number of Deaths in the United States With Ulcer Disease as the Primary Cause, 1960-79. 15	
3. Mortality Rates in the United States for Deaths Due to Ulcer Disease, 1953-78	16
4. Number of U.S. Hospital Discharges With Ulcer Disease Diagnoses, 1966-78	16
5. Ulcer Disease in the United States According to the Health Interview Survey, NCHS	17
6. Costs of Ulcer Disease in 1975 as Estimated by NCDD and SRI	19
7. Costs of Ulcer Disease in 1975 and 1977 as Estimated by SRI.	22

Table No.	Page
8. NCHS and CPHA Data on Number of Selected Surgical Procedures in the United States, 1966-78.	22
9. Components and Measures of Components in a Benefit-and-Cost Analysis of Cimetidine. 26	
10. Short-Term, Double-Blind, Placebo-Controlled Studies of Cimetidine: Effect on Duodenal Ulcer Healing	29
11. Short-Term, Double-Blind, Placebo-Controlled Studies of Cimetidine: Effect on Gastric Ulcer Healing	31
12. Short-Term, Double-Blind, Placebo-Controlled Studies of Cimetidine: Effect on Duodenal Ulcer Pain Relief	32
13 Short-Term, Double-Blind, Placebo-Controlled Studies of Cimetidine: Effect on Gastric Ulcer Pain Relief.	33
14. Controlled Trials of Maintenance Cimetidine in Peptic Ulcer.	36
15. Results of Treatment With Two Hypothetical Subpopulations of Ulcer Patients: Type A More Resistant to Treatment and Prone to Relapse Than Type B.	37
16. Short-Term, Double-Blind, Placebo-Controlled Studies of Cimetidine: Effect on Antacid Consumption.	40
17. Number of Selected Surgical Procedures in the United States, 1966-78	41
18. Proportion of Patients With First-Listed Diagnosis of Ulcer Disease Having Surgery, 1966-78	43
19. Number and Rate of All and Selected Abdominal Surgical Procedures in the United States, 1970-78.	43
20. Percentage Cost Savings Estimated From Robinson Associates Study	56

LIST OF FIGURES

Figure No.	Page
1. Benefit-and-Cost Model for Medical Interventions	8
2. Number of Deaths in the United States With Ulcer Disease as the Primary Cause, 1966-79. . 15	
3. U.S. Hospital Discharges With Ulcer Disease Diagnoses, All Sites, 1966-78	17
4. Paradigm Decision Tree: Cimetidine and Alternative Intervention Strategies	26
5. NCHS Data on Number of Selected Surgical Procedures in the United States, 1966-78.	42
6. CPHA Data on Number of Selected Surgical Procedures in the United States, 1966-78.	42
7. Number of Deaths in the United States From Ulcer Disease, 1976-79	46